Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2008-01-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
NCT00331500
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
NCT01159769
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
NCT02322216
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
NCT00818805
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
NCT00578929
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
olopatadine then placebo
participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
olopatadine
olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
placebo
placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
placebo then olopatadine
participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
olopatadine
olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
placebo
placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
olopatadine
olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
placebo
placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy volunteers (no major illnesses or active symptoms)
Exclusion Criteria
* Pregnant or nursing women
* Women wishing to become pregnant during the study's duration
* Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
* Dermatographism as evidenced on skin testing on visit 1
* Chronic urticaria active within the past 6 months
* Severe hypertension
* Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
* Inability to provide informed consent
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanderbilt University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Michael Fahrenholz
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt Asthma, Sinus and Allergy Program Research
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
071260
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.